CERo Therapeutics Inc. (CERO)
CERo Therapeutics Statistics
Share Statistics
CERo Therapeutics has 3.03M shares outstanding. The number of shares has increased by 1911.64% in one year.
| Shares Outstanding | 3.03M |
| Shares Change (YoY) | 1911.64% |
| Shares Change (QoQ) | 57.91% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 2.06M |
| Failed to Deliver (FTD) Shares | 432.53K |
| FTD / Avg. Volume | 61.41% |
Short Selling Information
The latest short interest is 292.69K, so 9.66% of the outstanding shares have been sold short.
| Short Interest | 292.69K |
| Short % of Shares Out | 9.66% |
| Short % of Float | 14.2% |
| Short Ratio (days to cover) | 1.25 |
Valuation Ratios
The PE ratio is -2831285.61 and the forward PE ratio is null. CERo Therapeutics's PEG ratio is -9580.12.
| PE Ratio | -2831285.61 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | -505.72 |
| P/FCF Ratio | -4725441.63 |
| PEG Ratio | -9580.12 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for CERo Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.65, with a Debt / Equity ratio of -0.11.
| Current Ratio | 1.65 |
| Quick Ratio | 1.65 |
| Debt / Equity | -0.11 |
| Debt / EBITDA | -0.64 |
| Debt / FCF | -1.02K |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-317.03 |
| Employee Count | 8 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 94.82K |
| Effective Tax Rate | -3.88% |
Stock Price Statistics
The stock price has increased by -99.68% in the last 52 weeks. The beta is 0.73, so CERo Therapeutics's price volatility has been higher than the market average.
| Beta | 0.73 |
| 52-Week Price Change | -99.68% |
| 50-Day Moving Average | 1.3 |
| 200-Day Moving Average | 9.54 |
| Relative Strength Index (RSI) | 30.49 |
| Average Volume (20 Days) | 704.32K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -2.93M |
| Net Income | -2.54K |
| EBITDA | -2.44M |
| EBIT | -2.44M |
| Earnings Per Share (EPS) | -0.39 |
Balance Sheet
The company has 96.87K in cash and 1.55M in debt, giving a net cash position of -1.46M.
| Cash & Cash Equivalents | 96.87K |
| Total Debt | 1.55M |
| Net Cash | -1.46M |
| Retained Earnings | -14.2M |
| Total Assets | 6.49M |
| Working Capital | -5.71M |
Cash Flow
In the last 12 months, operating cash flow was -1.52K and capital expenditures 4, giving a free cash flow of -1.52K.
| Operating Cash Flow | -1.52K |
| Capital Expenditures | 4 |
| Free Cash Flow | -1.52K |
| FCF Per Share | 0 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CERO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for CERO.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Jan 8, 2025. It was a backward split with a ratio of 1:100.
| Last Split Date | Jan 8, 2025 |
| Split Type | backward |
| Split Ratio | 1:100 |
Scores
| Altman Z-Score | -21.19 |
| Piotroski F-Score | 0 |